Neupro - 2007 FDA approvals

Drug: Neupro (rotigotine)
Indication: Parkinson's
Company: Schwarz BioSciences
Approval Date: May 9, 2007

Scoop: Neupro is a non-ergot dopamine agonist skin patch designed to treat symptoms of early Parkinson's disease. Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease. Rotigotine was approved by the EMEA in 2006.

More News:
Schwarz Pharma wins OK for Parkinson's patch. Report
Schwarz seeks new approval for Neupro. Report

Neupro - 2007 FDA approvals
Read more on

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i